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ABBREVIATIONS 
AA amino acid 
AC adenylate cyclase 
Adc adenosine 4’-dehydroxymethyl-4’-carboxylic acid moiety 
Ahx 6-aminohexanoic acid moiety 
AMSE 5-(2-aminopyrimidin-4-yl)selenophene-2-carboxylic acid 
moiety 
AMTH 5-(2-aminopyrimidin-4-yl)thiophene-2-carboxylic acid 
moiety 
ARC adenosine analogue and oligoarginine conjugate 
ARC-902 Adc-Ahx-(DArg)6-NH2 
ARC-1063 AMTH-Ahx-DArg-Ahx-(DArg)6-DLys(Alexa Fluor 647)-
NH2 
ARC-1139 AMSE-Ahx-DArg-Ahx-(DArg)6-DLys(PromoFluor-647)-
NH2 
ARC-1182 Adc-Ahx-DArg-Ahx-(DArg)6-DLys(PromoFluor-647)-NH2 
ARC-Lum ARC-type probe possessing protein-induced luminescence 
signal with microsecond-scale lifetime 
ARC-Lum(Fluo) ARC-Lum probe conjugated with a fluorescent dye 
ATP adenosine-5’-triphosphate 
C9H6 Chinese hamster ovary cell line stably expressing genetically 
engineered PKA subunits 
cAMP cyclic adenosine 3’,5’-monophosphate 
FA fluorescence anisotropy 
FRET Förster-type resonant energy transfer 
H89 N-[2-bromocinnamylamino)ethyl]-5-isoquinoline 
sulfonamide 
His-tag AA sequence of hexahistidine 
HTS high-throughput screening 
IC50 half maximal inhibitory concentration 
ITC  isothermal titration calorimetry 
KD equilibrium dissociation constant determined by direct 
binding 
Kd equilibrium displacement constant 
koff dissociation rate constant for full break up of complex 
kd,n/ka,n individual dissociation/association rate constant  
kon total association rate constant 
PEG  polyethylene glycol 
PKA cAMP-dependent protein kinase A holoenzyme 
PKAc catalytic subunit of PKA 
PKAr regulatory subunit of PKA 
PKB(Akt) protein kinase B, RAC Ser/Thr protein kinase, gene name 
AKT 
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PKI natural heat-stable peptide inhibitor of PKAc 
PPI protein-protein interaction 
ROCK Rho-associated protein kinase 
SAR structure-affinity relationship 
SPR  surface plasmon resonance 
TR time-resolved 
TR-FRET time-resolved Förster-type resonant energy transfer 
TRL time-resolved luminescence 
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1. INTRODUCTION 
A living cell is a highly complex and dynamic system. Proteins have the leading 
role in cellular signaling by participating in non-covalent interactions and 
catalyzing enzymatic reactions. Key regulators of signaling pathways are 
protein kinases (Bononi et al. 2011). Intracellular information exchange (signal 
transduction) between chromosome and extracellular matrix through a single 
pathway alone involves a cascade of protein kinases. While each step within 
signal mediation is conserved, significant cross-talk between different pathways 
can occur (Nishi et al. 2015). Abnormal activity of protein kinases, frequently 
resulting from altered gene expression (Schenk and Snaar-Jagalska 1999), entail 
many diseases that are difficult to address in terms of therapy (Yoeli-Lerner et 
al. 2006). In normally functioning signal transduction, a specific interaction 
between at least two proteins is necessary. Interactions between protein 
complexes that do not involve enzymatic reaction can be defined by the strength 
of interaction. Such protein-protein interactions (PPIs) range from very weak to 
very strong, depending on the contact area of interacting proteins and amino 
acid “hot spots” involved (Chen et al. 2013). There is increasing evidence of 
health disorders resulting from the defects in the formation of protein 
complexes. This knowledge has led the construction of compounds that disrupt 
or reinforce the interaction between proteins for therapeutic uses (Arkin et al. 
2014; Wells and McClendon 2007; Thiel et al. 2012). 
Various methods have been developed for studying the diverse superfamily 
of protein kinases, PPIs, and related small molecule ligands (Rao et al. 2014; 
Glickman 2012). Among these, fluorescence anisotropy (FA)- and Förster-type 
resonant energy transfer (FRET)-based methods are widely used due to their 
relative simplicity. 
In this thesis, novel protein binding-responsive organic bifunctional probes 
(ARC-Lum probes) possessing long-lifetime (microsecond scale) photolumi-
nescence were characterized in protein kinase binding assays in time-resolved 
(TR) format. This setup greatly reduced some of the shortcomings of FA- or 
fluorescence intensity (FI)-based assays, such as background fluorescence, 
leading to superior outcome in biochemical assays, and demonstrated the 
capability to monitor the activity of protein kinases in cells. The low TR signal 
of unbound ARC-Lum probes revealed their potential in the characterization of 
dissociation kinetics of a complex between protein kinase and competitive 
inhibitor. Kinetic characterization of biocomplexes may reveal crucial mecha-
nistic information, not available from equilibrium constants. Measurement of 
rate constants in various applications led to the finding that bifunctional ligands 
behave differently from monofunctional ligands – the dissociation of a complex 
between a bifunctional ligand and target protein is facilitated by competitive 
inhibitors.  
The application of ARC-Lum probes together with the TR measurement 
mode allowed the characterization of a new series of bifunctional ligands 
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possessing affinities down to one-digit picomolar value. These highly potent 
ligands were applied for characterization of strong PPIs between heteromers of 
PKA holoenzyme. The high affinity of 5-TAMRA functionalized ARC-1413 
towards PKAc (Kd = 5 pM) allowed accurate determination of affinity of PKA 
subunits. The disruption of PKA holoenzyme was confirmed by a decrease in 
FRET between genetically engineered PKA subunits after supplementing the 
bifunctional ligand ARC-1411. Described technique is a promising approach for 
disruption of strong PPIs that possess too high binding energy to be cleavable in 
presence of monofunctional ligands.  
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2. LITERATURE OVERVIEW 
2.1. Proteins 
The ultimate regulators of living organisms are nucleic acids, their translation 
products, proteins have a broad variety of functions and can be more difficult to 
address in the sense of modeling, predicting, and analyzing. Proteins are poly-
mers of amino acid (AA) residues that constitute 100–300 g/L (approximately 4 
mM) of an eukaryotic cell (Theillet et al. 2014).  
The sequence of AA residues (primary structure) in a protein is determined 
by a set of codons, triplets of mRNA nucleotides. The primary structure of a 
specific protein dictates its secondary, tertiary, and quaternary structures 
(Anfinsen 1973). Comprehension of protein folding is of paramount importance 
to understand biological processes. Folding of a protein through interactions 
between AA residues is described as a “hierarchical process”, in which an 
unfolded translated protein possesses nucleation centers that form local 
segments (α-helixes, β-sheets, etc) and grow until protein has reached a native 
conformation (Honig et al. 1976). Aside this well-known basic principle, the 
exact understanding of and mechanical modeling to predict folding and 
subsequent importance in the biomolecular system has been challenging.  
Developments led to the introduction of WSME model in 1990-s (Wako and 
Saito 1978; Muñoz and Eaton 1999). With two assumptions, this model 
calculates free-energy landscape for a protein, giving numerical values for the 
folding of N-terminal and C-terminal halves of the respective protein. WSME 
model explains many aspects of AA sequence structure arrangements relatively 
well, involving pathways of folding and unfolding, positioning of each 
constituent AA, and minimum energy of the native state. More importantly, this 
model can also account for multi-domain proteins and kinetic parameters of 
folding (Inanami et al. 2014). There are methods capable of recording protein 
folding experimentally, such as fluorescence techniques, IR, NMR, and CD 
(Buchner et al. 2011), which use is often limited by complexity and throughput 
of the assay. The kinetic characterization of folding for a significant portion of 
the whole human proteome with over 17 000 known proteins and few thousand 
missing proteins (Kim et al. 2014; Baker et al. 2017) with theoretical calcu-
lations is, therefore, more realistic in the near future compared to experimental 
techniques. The general understanding is that secondary structure elements and 
single-domain proteins fold with a limited speed (1 µs) and follow a simple 
equation N/100 µs, with N being the number of AA residues (Kubelka et al. 
2004). Multi-domain proteins tend to show longer folding times, as the 
maturation of full structure involves the achievement of energetic minimum of 
an ensemble of constituents (Arai et al. 2011).  
Making general assumptions about the specific protein can lead to a drastic 
error, as even some globular proteins fold in minutes and tens of minutes 
(Finkelstein et al. 2017). Physically prolonged folding times of proteins 
contradict to the overall efficiency of cellular operations, for example, even the 
13 
translation of an average protein (440 AA) in eukaryote completes in 1–2 
minutes (Újvári et al. 2001). 
 
 
2.1.1. Interactions between proteins 
Correctly folded protein can subsequently contribute to the normally 
functioning cycle of a living cell. Without interactions between proteins, termed 
as protein-protein interactions (PPIs), the cellular signaling, and consequently 
cell-based life-forms, would not exist. The collection of PPIs is referred to as the 
interactome. According to human proteome, the human interactome is estimated 
to consist of 280 000 PPIs (Chatr-Aryamontri et al. 2015), out of which only 
14 000 interactions have been confirmed experimentally (Rolland et al. 2014). 
Excluding internal interactions (intra-domain and domain-domain within one 
primary sequence), PPIs can be divided into four general categories: homo-
obligomers, homo-complexes, hetero-obligomers, and hetero-complexes (Ofran 
and Rost 2003). Obligomers refer to obligatory or permanent interactions that 
rarely participate in signaling, complexes denote transient PPIs that are 
responsible for signal transduction (Ofran and Rost 2003). The majority of 
information is transferred specifically through interactions of hetero-complexes. 
Interfaces between proteins are formed preferably by hydrophilic AA residues 
(Arg, Asn, Gln, His), with the exception of hydrophobic Tyr residue, and the 
buried areas comprise hydrophobic residues (Ile, Val, Leu, Phe) (Yan et al. 
2008). The contact area of PPIs spans a wide range from 300 to 3500 Å2. There 
is little to no correlation between the strength and size of PPIs, as the 
dissociation constant of the complex has been shown to range from 10 µM to 
100 pM for similarly sized (1500 Å2) interfaces (Chen et al. 2013). Importantly, 
a major part of the interaction strength is caused by only a fraction of AAs of 
the interface termed “hot spots”. This was demonstrated for the interaction 
between human growth hormone (hGH) and its receptor, in which 11 AAs 
contributed more than 4.18 kJ/mol and two AAs more than 16.7 kJ/mol into 
(negative) binding free energy out of 30 AAs at the interface (Clackson and 
Wells 1995). 
A systematically studied and diverse PPI partner is SRC homology domain 2 
(SH2). SH2 is conserved in 111 proteins. It is essential in mediating insulin and 
growth factor signaling (Liu et al. 2011). KD values range from sub-nanomolar 
to sub-millimolar values for PPIs between SH2-comprising proteins and receptors 
(Liu et al. 2012).  
In addition to folded proteins, the importance of intrinsically unstructured 
proteins (IUPs) in the PPI context has become evident (Dyson and Wright 
2005). These proteins can exist under physiological conditions without any 
secondary structure or contain unstructured regions. Database of protein dis-
order (DisProt.org, accessed 01.06.2017) currently reports 557 eukaryotic 
proteins with unstructured regions, which range from tens to hundreds of AAs 
(Piovesan et al. 2017). Binding of IUP to its target protein can inhibit or induce 
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structural changes to the target or IUP itself. An example of fully IUP is the 
kinase-inducible domain (KID, gene name CREB1) when not bound to its 
target, cAMP-response-element-binding protein (CREB) binding protein (CBP) 
(Sugase et al. 2007). KID is a 341 AA long unstructured protein, which binds to 
KIX domain on CBP with a KD of 1.5 µM, accompanied by the formation of 
two α-helixes within its structure (Sugase et al. 2007). CBP is a large (2442 
AAs) and exemplary protein with numerous PPIs, while up to 50% of CBP 
itself is unstructured (Dyson and Wright 2005). In the case of oxygen defi-
ciency, hypoxia-inducible transcription factor 1α (HIF1α) winds tightly around 
transcriptional-adaptor zinc-finger (TAZ) domain 1 within CBP (Dames et al. 
2002). This strong interaction (KD = 7 nM) is possible due to the loose nature of 
both partners, which would require a larger interaction area for two globular 
structured proteins. In this regard, a disorder in the protein structure in complex 
living organisms allows stronger interactions at the lower mass of proteins, 
estimably resulting in 15–30% smaller cellular volume (Gunasekaran et al. 
2003). 
 
 
2.1.2. Post-translational modifications 
In addition to approximately 20 000 human protein-coding genes, alternative 
splicing and post-translational modifications may altogether result in millions of 
different protein variants (Jensen 2004). There are over 100 different 
modifications that have specific outcomes for specific proteins, such as protein 
localization or folding and subsequent participation in PPIs (Khoury et al. 
2011). A single protein may be subjected to numerous post-translational modi-
fications simultaneously. For example, the functioning of HIF1α is regulated by 
17 post-translational modification sites according to UniProt database 
(UniProt.org, accessed 01.06.2017), six of which are targets of phosphorylation, 
two sites are prone to SUMOylation, and three for ubiquitination. Phosphory-
lation is the most frequent and universal post-translational modification in the 
biological kingdom (Beltrao et al. 2013). 
 
 
2.2. Protein kinases 
The superfamily of protein kinases with over 500 members is one of the largest 
in the set of mapped human protein-coding genes (Manning 2002). Protein 
kinases are transferases that functionalize target proteins with phosphoryl groups 
from nucleotides. Phylogenetically, protein kinases are divided into seven main 
groups: AGC (PKA, PKC, PKG, and ROCK families), CAMK, CMGC, CK1, 
STE, TK, and TKL.  
According to experimental data, over 10 000 proteins in human proteome are 
phosphorylatable, with a total of 86 000 phosphorylation sites (Vlastaridis et al. 
2017). The vast importance of correct phosphorylation in sustaining normal 
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signaling means that aberrant functioning of protein kinases entails health 
disorders. The dysfunctional activity of protein kinases has been linked to a 
number of diseases, from diabetes to neurological diseases and cancer 
(Arencibia et al. 2013). 
 
 
2.2.1. cAMP-dependent protein kinase 
The catalytic subunit (PKAc) of cAMP-dependent protein kinase (PKA) is an 
extensively characterized member of the AGC-group kinases. Three genes, 
PRKACA, PRKACB, and PRKACG encode PKA catalytic subunit isoforms 
PKAcα, PKAcβ, and PKAcγ, respectively (Turnham and Scott 2017). Isoforms 
PKAcα and PKAcβ are expressed in various tissues, while PKAcγ is expressed 
only in testis. Reportedly, there is the fourth gene PRKX that leads to expression 
of PKAc isoform that is involved in neural development and sexual dif-
ferentiation (Huang et al. 2016). While the primary sequence is only 48% 
similar to PKAcα, PRKX product exhibits extensively conserved sequences in 
catalytically important regions. 
PKA activity is mostly regulated by the levels of the secondary messenger 
cAMP. Extracellular effectors activate adenylate cyclase (AC), which catalyzes 
ATP conversion to cAMP. At low cAMP levels, PKA exists as a holoenzyme 
comprising AKAP (A-kinase anchor protein)-bound PKA regulatory (PKAr) 
subunit dimer and two PKA catalytic (PKAc) subunits (PKAr2:PKAc2); acti-
vation of AC leads to elevated concentrations of cAMP, four cAMP molecules 
bind to the PKAr dimer and the resulting conformational change leads to release 
of two catalytic PKA subunits for phosphorylation of downstream targets 
(Taylor et al. 2004). Myristoylation at N-terminal glycine residue of PKAc can 
force its localization to the membrane, greatly reducing the diffusion of PKAc 
and supporting the phosphorylation of protein substrates, especially intracellular 
receptor sites (Tillo et al. 2017). As a negative feedback mechanism, PKAc 
activates phosphodiesterases (PDEs), for example, PDE4D3, which decrease 
cAMP concentration and promote the reformation on PKA holoenzyme (Terrin 
et al. 2012). However, in case PKAc is localized onto the membrane by 
myristoyl group, the slow escape or diffusion from the membrane to PKAr may 
greatly hinder the reduction of catalytic activity. 
In addition to the release from the PKAr subunit, the catalytic activity of 
PKAc is possible only after two phosphorylation events within its structure: 
autophosphorylation at Ser338 and phosphorylation of Thr197 by PDK1. Two 
cAMP-independent PKA regulation pathways have been described: IκB 
interaction with PKAc and Smad4 binding to PKAr (Zhong et al. 1997; Zhang 
et al. 2004). 
Free and catalytically active PKAc phosphorylates roughly 100 protein 
targets (Kreegipuu et al. 1998), including CREB for association with CBP. The 
activity in the cytosol is reduced by the decrease in cAMP levels, however, 
PKAc transported into the nucleus is bound by natural heat-stable protein kinase 
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inhibitor (PKI) (Chen et al. 2005). PKI binds to the substrate-binding site of 
PKAc, inhibiting the latter enzyme and transporting PKAc to the cytosol. Well-
studied interactions involving PKAc give insight into numerous PPIs that 
participate in signaling cascade from the viewpoint of a single protein. 
Signaling cascade of PKAc can be modulated differently at each PPI intraface 
(interaction area of one protein partner in PPI), for example by targeting 
AKAP:PKAr or PKAr2:PKAc2. However, the disruption of PKA holoenzyme is 
a complicated task due to the strong PPI (KD = 100 pM) between PKAr and 
PKAc subunits (Cheung et al. 2015). 
 
 
2.2.2. Rho-associated protein kinase 
Rho-associated protein kinase (ROCK) is a ubiquitously expressed kinase in 
human organism that belongs to the AGC-group of protein kinases. ROCK has 
two isoforms: ROCK1 and ROCK2 with molecular weights of 158 kDa and 161 
kDa, respectively. The protein with high molecular weight incorporates several 
domains: kinase domain in the N-terminus, coiled-coil domain, Rho-binding 
domain, and pleckstrin homology (PH) domain in the C-terminus (Leung et al. 
1995; Jacobs et al. 2006). ROCK isoforms do not specifically require any 
posttranslational modifications in kinase domain for catalytic activity. Instead, 
phosphorylation by ROCK is regulated by Rho-binding and PH domains, which 
interact with and autoinhibit the kinase domain. Binding to Rho-GTPases (Rho, 
CDC42, etc.) alters the conformation of ROCK: Rho-binding domain interacts 
with membrane-associated Rho-GTP, PH domain binds to negatively charged 
lipids, and hydrophobic motif within the kinase domain enforces two ROCK 
subunits to form a dimer (Pearce et al. 2010). Triggered conformational change 
activates ROCK for downstream signaling. 
Phosphorylation of over 30 substrates by ROCK regulates cytoskeletal 
dynamics and morphology/contraction of a cell (Schofield et al. 2013). Well-
studied target myosin-binding subunit (MYPT1) phosphorylation at Thr696 and 
Thr855 is mediated by ROCK, which leads to MYPT1 dissociation from 
myosin light chain phosphatase (MLCP) (Loirand and Touyz 2015). Myosin 
light chain can bind to actin filament after phosphorylation by myosin light 
chain protein kinase (MYLK), resulting in muscle contraction (Stull et al. 
2011). 
 
 
2.2.3. RAC Ser/Thr protein kinase 
RAC serine/threonine protein kinase (PKB, also known as Akt) isoforms PKBα, 
PKBβ, and PKBγ are expressed in numerous human tissues (Petryszak et al. 
2016). Similarly to ROCK, PKB incorporates a PH domain. PH domains of 
PKB have been found to interact with T-cell leukemia/lymphoma 1 (TCL1) 
oncoprotein, resulting in increased PKB activity, and inosine-5’-monophosphate 
dehydrogenase (IMPDH), leading to increase in IMPDH enzymatic activity 
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(Brazil et al. 2002). The central importance of PH domain lies in its interactions 
with phosphatidylinositol-3,4,5-triphosphates and promotion of PKB locali-
zation onto cell plasma membrane (Yang et al. 2002). Membrane-association is 
necessary for subsequent phosphorylation of PKB at Thr305/308/309 residues 
by phosphoinositide-dependent-kinase-1 (PDK1) (Alessi et al. 1996). Full 
activation of PKB requires phosphorylation at Ser473/475/576 residues by the 
mammalian target of rapamycin (mTOR) (Sarbassov 2005; Alessi et al. 1996).  
The substrate consensus sequence of PKB lacks conformity as the only 
regularity between numerous substrates is Arg in position –3 from 
phosphorylation site of Ser/Thr (Brazil and Hemmings 2001). Substrates 
phosphorylated by PKB are key regulators of cell survival, proliferation, and 
growth, including Bcl-2-associated death promoter (BAD), thereby preventing 
the cell from entering programmed cell death, and glycogen synthase kinase 3 
(GSK3), which is inactivated for glycogen production (Shaw et al. 1997; Datta 
et al. 1997).  
 
 
2.3. Ligands 
Detailed understanding of protein structure and interactions in signaling 
pathways has enabled the construction of molecules with remarkable affinity 
and selectivity towards the target for influencing, in most cases, inhibiting a 
specific process. Lead molecules are studied and subjected to modifications, 
and promising candidate molecules are meticulously characterized bio-
chemically, in vitro, in vivo, and in clinical trials. Only a few candidates 
succeed to comply with the requirements in clinical trials and can be marketed 
as drugs. Currently, 82.4% of marketed drugs are distributed amongst 8 protein 
family classes: 7-transmembrane family 1 (30.3%), nuclear receptors (13.5%), 
voltage-gated ion channels (8.0%), reductases (7.6%) ligand-gated ion-channels 
(7.0%), electrochemical potential-driven transporters (6.9%), kinases (5.9%), 
and proteases (3.4%) (Santos et al. 2016). Compounds targeting kinases and 
proteases make up 8.3% of the drugs, however, their clinically non-approved 
inhibitors in European Bioinformatics Institute (ChEMBL) database form up to 
27.2% of compounds and protein kinase-targeting drugs approved between 
2011–2015 constitute 28% of all approvals (Santos et al. 2016). 
In 1997, Lipinski et al. analyzed the structures of approved drugs and 
postulated “The Rule of Five” to aid the rational design and discovery of novel 
candidates for oral drugs (Lipinski et al. 1997). According to these rules, a 
molecule possessing more than five hydrogen bond donors and ten hydrogen 
bond acceptors, molecular weight over 500 Da, and octanol-water partition 
coefficient (log P) over five is less likely to permeate cell plasma membrane 
and should not proceed into clinical trials. These rules were insightful and 
helped to avoid failures in later stages of drug development, however, new 
knowledge acquired within two decades has made it clear that many complex 
diseases need a different approach for successful treatment. For example, some 
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drug candidates in clinical trials greatly exceed the molecular weight limit of 
500 Da (Agarwal et al. 2014). 
The first requirement of a promising lead molecule is sufficient affinity 
towards its target. The affinity or interaction strength is expressed as 
equilibrium dissociation constant (KD) of the complex between target protein 
and inhibitor (Equation 1A). 
 
                        A                                       B 
ܭୈ =
[ܲ][ܫ]
[ܲܫ] 																			ln	ܭୈ =
∆ܩ୆଴
ܴܶ =
∆ܪ୆଴ − ܶ∆ܵ஻଴
ܴܶ  
 
Equation 1. A) KD, the equilibrium dissociation constant of a complex between protein 
and inhibitor; [P], the equilibrium concentration of free protein; [I], the equilibrium 
concentration of free inhibitor; [EL], the equilibrium concentration of protein:inhibitor 
complex. B) ∆ܩ୆଴, standard free energy change of the binding between protein and 
inhibitor; R, ideal gas constant; T, absolute temperature; ∆ܪ୆଴, standard enthalpy change 
of binding; ∆ܵ୆଴, standard entropy change of binding. 
 
KD of the complex decreases with increasing strength of the interaction. KD can 
be related to standard free energy change of binding, ∆ܩ୆଴ (opposite sign to 
∆ܩ଴) (Equation 1B) that comprises both enthalpic (∆ܪ୆଴) and entropic (∆ܵ୆଴) 
change upon binding (Du et al. 2016). Decreasing ∆ܩ୆଴ and therefore KD is 
possible by strengthening interactions (negative ∆ܪ୆଴) or inflicting disorder 
within protein or environment (positive ∆ܵ୆଴) upon binding. However, inhibitor 
with very strong interaction consequently brings along structural order and loss 
in degrees of freedom within protein and optimizing both ∆ܪ୆଴ and ∆ܵ୆଴ is 
frequently conflicting. Most of the inhibitors are enthalpy-driven, as the 
hydrogen-bond interactions are easily predicted and calculated based on 
available crystal structures of proteins (Olsson et al. 2008). In the later stages of 
drug development, inhibitors can be designed structurally more rigid to increase 
∆ܵ୆଴ and gain in overall affinity, while retaining strong interactions. 
 
 
2.3.1. Kinetics of ligand:protein complexes 
The association and dissociation rate constants between a ligand and a protein 
are important parameters that are often overlooked in biochemical 
characterization of interactions. The association rate constant (kon) describes the 
speed of colliding and complex formation between two molecules according to 
the rate of second-order reaction (M–1s–1). The dissociation rate constant (koff) 
describes the break-up of a complex, mostly following the rate of a first-order 
reaction (s–1). Kinetic parameters are directly related to KD according to Equation 
2A. However, in most cases with biomolecular targets, the interaction can be 
divided into two distinct steps: formation or breakdown of initial complex, and 
conformational change (induced fit) of protein (Meyer-Almes 2015). 
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                                      A                                       B 
ܭୈ =
݇୭୤୤
݇୭୬ 																												݇୭୤୤ =
1
߬ 
 
Equation 2. A) koff, dissociation rate constant of ligand:protein complex; kon, association 
rate constant of ligand:protein complex; B) τ, the residence time of the complex. 
 
Structure-affinity relationship (SAR) studies of lead compounds were mainly 
focusing on KD, omitting the possibility to steer the selectivity towards the 
desired target by increasing residence time (Equation 2B). After the 
introduction of the term and its importance, improving the residence time of a 
ligand on its target has become a widely accepted strategy (Copeland et al. 
2006). The prolonged residence time of a ligand towards specific target 
compared to off-target proteins results in improved outcome in a complex 
system (e.g., cellular environment), as the ligand is kinetically occupied in 
complex with the target. In parallel, drug molecule binding to and quickly 
dissociating from off-target results in alleviated toxic effects (Lu and Tonge 
2010). A successful example is Gleevec (Imatinib), the first selective cancer 
therapeutic for Tyr-protein kinase Abl (Manley et al. 2002). Kinetic analysis 
revealed that although Abl and protein kinase Src share almost identical binding 
site, the residence time of Gleevec on Abl is 60-fold greater compared to Src 
(Agafonov et al. 2014). 
 
 
2.3.2. Monofunctional ligands 
In the current context, monofunctional ligand is referred to as a molecule which 
occupies a single distinct region on a protein. In most cases, ligands behave as 
inhibitors for disruption of the interaction between protein and its substrate, 
while the development of stabilizers of PPIs has the reciprocal purpose of 
reinforcing the interaction. Depending on the mechanism of action, 
monofunctional ligands can be divided into a variety of groups, not all of which 
are discussed here. 
Covalent or irreversible monofunctional ligands bind to and form a covalent 
bond with the target protein. Covalent modification is usually accompanied with 
long inhibition of the natural action of the protein. An early successful example 
of this approach is the use of acetylsalicylic acid which suppresses inflammation 
by acetylating prostaglandin-endoperoxide synthase (PTGS), despite that the 
approval for its use as a drug preceded the resolving of the exact mechanism by 
85 years (Roth and Majerus 1975). Extensive research on covalent inhibitors of 
protein kinases has largely been unfruitful due to the conserved kinase site within 
kinome. An irreversible Bruton tyrosine kinase (BTK) inhibitor is a successful 
example that targets uncommon binding site holding a cysteine residue (Cys481), 
granting higher selectivity (Honigberg et al. 2010). Ibrutinib has been approved 
for therapeutic use in rare lymphoma, Waldenström macroglobulinemia, in which 
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BTK is constitutively active and contributes to the suppression of apoptosis-
induced cell death (Abeykoon et al. 2017; Yang et al. 2013).  
Reversible monofunctional ligands form a transient non-covalent interaction 
with the target protein. These inhibitors can bind directly to the interaction site 
(active site of the enzyme) or allosteric site. The comprehensive understanding 
of PPI interfaces and signaling pathways has only recently increased the 
systematic study of inhibiting PPIs. The potency of small molecules for binding 
PPI interfaces is usually small, restricted by physical limitations to molecular 
weight compared to large interaction area between the interacting proteins. For 
example, most small molecules have a micromolar affinity for disruption of PPI 
between specific SH2-domain and receptor, while inhibitors targeting specific 
SH2 interactions achieve low-nanomolar affinity (Kraskouskaya et al. 2013). 
An emerging role in targeting PPIs is the stabilization of the interaction by 
ligand-binding. This mechanism has been successfully demonstrated with 
compound RO-2443 on double minute 2 (MDM2) and double minute 4 (MDM4) 
interaction. RO-2443 binds into the interface MDM2/MDM4 and stabilizes the 
interaction, preventing the protein complex from rearranging and ubiquitinating 
tumor suppression antigen p53 by the really interesting new gene 1 (RING1) 
domain, promoting apoptosis of cancer cells (Graves et al. 2012). 
A protein kinase has two substrates: a nucleotide, typically ATP, and a 
protein. Reversible monofunctional inhibitor competitive with ATP has to over-
come millimolar intracellular concentration of the latter compound (Ataulla-
khanov and Vitvitsky 2002; Knight et al. 2007). Regardless, the growing 
number of cancer incidences has driven the inevitable need for its 
chemotherapy. Protein kinases are obvious inhibition targets due to their role in 
aberrant signaling in cancer cells and currently, 23 out of 28 FDA-approved 
small-molecule protein kinase drugs are reversible ATP-competitive inhibitors 
(Wu et al. 2016). Half of these drugs also bind an adjacent site simultaneously 
with the ATP-site, but no drugs are available for remote allosteric sites of 
protein kinases. In contrast, protein substrate-competitive monofunctional 
inhibitors have the potential to achieve high selectivity. However, protein 
substrate-competitive inhibitors target less defined binding site over the large 
surface area, resulting in too low affinity for sufficient efficacy in vivo or fail to 
cross cell plasma membrane due to high molecular weight and polarity 
(Bogoyevitch et al. 2005). 
 
 
2.3.3. Bifunctional ligands 
Bifunctional ligands that target proteins are generally reversible and occupy two 
distinct regions of the protein simultaneously. These regions may be identical, if 
located on separated proteins a protein homodimer is formed (Zhou et al. 2008). 
However, most bifunctional ligands for binding proteins are heterobifunctional 
and designed for inducing the formation of protein heterodimers and thereby 
trigger a subsequent biological response (Corson et al. 2008). The interactions 
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within triple (ternary) complex composed of two proteins and a bifunctional 
ligand may be reinforced by the effect from avidity and favorable contacts 
between proteins (Vauquelin and Van Liefde 2012; Zhou et al. 2008). 
The application of bifunctional inhibitors has been mostly studied for 
dimerization or stabilization of protein complexes (Spencer et al. 1993) and less 
research has been described related to their application for disruption of PPIs. A 
successful example is a bifunctional ligand consisting of two pentapeptides 
linked by PEG that bind to postsynaptic density protein 95 (PSD95) domains 
PDZ1 and PDZ2 (Bach et al. 2012). This disrupts the PSD85 interaction with 
both NMDA ionotropic receptor and nitric oxide synthase (nNOS), inhibiting 
the generation of nitric oxide and protecting cells from the damage. 
Successful construction of bifunctional ligands to target protein kinases was 
first reported for PKC (Ricouart et al. 1991). In the case of protein kinases, 
heterobifunctional inhibitor occupies both the hydrophobic ATP-pocket and 
protein substrate-binding site on a single target protein simultaneously. A 
common approach for designing a bifunctional ligand is the conjugation of two 
moieties with known binding characteristics by a linker unit (Loog et al. 1999; 
Parang et al. 2001). Extensive structure-affinity research (SAR) and co-crystal 
analysis of adenosine analogues and arginine-rich peptide conjugates (ARCs) 
highlighted the importance of linker region between two moieties (Lavogina et 
al. 2010a; Pflug et al. 2010). The optimal length of the linker leads to substantial 
increase in affinity and offers the possibility to improve selectivity towards 
target protein. The binding free energy of a bifunctional ligand with its target 
protein is the sum of binding free energies of two interacting moieties plus an 
additional gain from ∆ܵ୆଴ of adjoining two moieties (Jencks 1981).  
 
 
2.4. Methods for studying protein kinases,  
protein-protein interactions, and inhibitors 
2.4.1. Protein kinase activity assays 
The activity of a protein kinase is measured by the rate at which its substrate is 
phosphorylated, corresponding to the enzyme unit (U), where 1 U equals the 
amount of protein kinase that phosphorylates 1 nanomole of the specific 
substrate within 1 minute at 30 °C (Hastie et al. 2006). Instead of physiological 
substrates, a phosphorylatable peptide sequence mimicking the substrate can be 
used (Macala et al. 1998). The classical method for assessing the activity is 
based on monitoring the migration of substrates, radioactively labelled 32P-ATP 
and peptide substrate on phospho-cellulose paper (Witt and Roskoski 1975). 
The high risk related to radioactive samples led to chromatography methods 
based on fluorophore-conjugated substrate peptides (Viht et al. 2005). Activity 
profiling has also been demonstrated in a high-throughput system with nanoliter 
volumes but is limited to glycerol-presence and substrate-product conversions 
that incorporate a large Stokes shift (Ma et al. 2005). In these activity assays, 
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Scheme 1. A) The monosubstrate reaction mechanism in the presence of competitive 
inhibitor: kcat, the rate constant of product formation; k1, the association rate constant;  
k–1, dissociation rate constant; E, enzyme; S, substrate; P, product; I, inhibitor. 
B) Equations for the rate of monosubstrate reaction: v0, initial velocity; [E]t, the total 
concentration of enzyme; [S], the concentration of substrate. C) Michaelis-Menten 
equation: KM, Michaelis-Menten constant; Vmax, the maximum rate of substrate 
conversion. 
 
Binding assays are a convenient alternative to monitoring substrate 
phosphorylation. Instead of application of two substrates, binding of the ligand 
to the catalytically active enzyme is employed. The unlabeled ligand can be 
used in heterogeneous biosensor assays, such as surface plasmon resonance 
(SPR) (Viht et al. 2007). SPR provides kinetic parameters in addition to the 
value of KD. A sensitive homogeneous setup requires the conjugation of the 
ligand with a fluorophore, resulting in a fluorescence probe suitable for use in 
various FI-based assays that differentiate between the free probe and 
probe:enzyme complex. Methods with fluorescence polarization/anisotropy 
(FP/FA) read-out can be used for measurement of both direct binding of the 
probe to the enzyme and displacement of the probe from the complex with a 
protein by an inhibitor (Owicki 2000). The FP and FA are interchangeable 
quantities, while the usage of FA is preferred as it accounts for total intensity 
(Equation 3). 
 
                           A                                                 B 
ܲ = ܫ|| − ܫ⏊ܫ|| + ܫ⏊ 																																ݎ =
ܫ|| − ܫ⏊
ܫ|| + 2ܫ⏊	 
 
Equation 3. P, polarization; I||, emission intensity parallel to incident light; I⏊, emission 
intensity perpendicular to incident light; r, anisotropy. 
 
one substrate is taken in excess and phosphorylation rate is monitored in time 
(Scheme 1A). The equation describing the resulting pseudo first-order reaction 
(Scheme 1B) is further simplified by Michaelis-Menten equation (Scheme 1C), 
where Vmax = kcat[E]t and KM . Each of these assays can be used for 
characterization of inhibitors, where the assay is repeated in the presence of 
various concentrations of the inhibitor (Scheme 1A). 
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FA assay is based on the difference of rotational speed of the free and protein-
bound fluorescent probe. Polarized excitation of free fluorescent probe rotating 
rapidly results in depolarization of emitted light, leading to decrease in I|| and 
low anisotropy value; upon binding to a target protein, rotation of fluorescent 
probe is hindered and anisotropy increases (Lakowicz 2006a). Despite the 
simplicity of FA assay, the affinity of fluorescent probe limits the highest 
affinity of competitive inhibitor under observation and the lowest concentration 
of the target protein (Huang Xinyi 2003). 
 
 
2.4.2. Protein interaction analysis 
Information regarding PPIs can be extracted using multiple methods that differ 
greatly in their nature. Each method has specific benefits and drawbacks, 
requiring the need for confirming the result in parallel by another method. 
Simple and low-cost option for discovering PPIs has been yeast two-hybrid 
(Y2H) assay. 
Y2H is a genetic method, in which transcription factor is split and fused 
separately with two proteins under observation, activating reporter gene if the 
two proteins interact (Fields and Song 1989). Despite aiding in the discovery of 
many PPIs, Y2H is prone to false-positives and does not describe mammalian 
interactome well with estimation of only 10 000 interactions (Sprinzak et al. 
2003). 
Co-immunoprecipitation (co-IP) technique is based on pull-down of antigen 
proteins onto the antibody-functionalized support and subsequent elution for 
analysis (Ren et al. 2003). Co-IP may detect protein complexes composed of 
many proteins and prepared surface can be used in multiple experiments. The 
analysis is limited to the specific antigen, making co-IP a good method for 
validation of interactions, but impractical for whole interactome analysis 
(Markham et al. 2007). Therefore, attention has been turned to simple native 
gel-electrophoresis (NE) to address the difficulties related to the PPI discovery 
in a universal manner (Camacho-Carvajal et al. 2004). For example, whole cell 
lysate is introduced to mild conditions that retain stable PPIs and the proteins 
co-migrate in an electric field. Optimized NE method is also capable of 
analyzing membrane protein interactions (Wittig and Schägger 2009).  
Y2H, co-IP, and NE techniques are frequently combined with mass-spectro-
metry (MS), which provides structural details (primary AA sequence) about the 
separated proteins or protein complexes (Farmer and Caprioli 1998). MS has 
been developed into highly capable technique for discovering PPIs from living 
cells by chemical cross-linking, subsequent cell lysis, proteolysis, and comparison 
of detected peptides against the database (Zhang et al. 2009).  
Lately, nuclear magnetic resonance (NMR) has been demonstrated as a 
perspective technique for characterization of PPIs. Compared to the capability 
of NE for detecting stable (KD < 1–10 µM) PPIs, a solution NMR can 
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additionally visualize transient (KD > 1 µM) PPIs, which for most methods are 
kinetically too labile to detect (Liu et al. 2016). 
PPIs that have been confirmed can be further characterized by using Förster-
type resonant energy transfer (FRET) phenomenon, in which interacting 
partners are fused with fluorescent proteins or chemical labels (Scheibner et al. 
2003; Mitra et al. 1996). FRET occurs between excited donor (D) molecule and 
ground-state acceptor (A) molecule as a non-radiative energy transfer, as 
revealed by the decrease of fluorescence intensity in the donor channel and its 
increase in acceptor channel (Lakowicz 2006b). FRET provides information 
regarding cellular localization and the dynamics of interacting partners in 
response to extracellular stimuli. 
Isothermal titration calorimetry (ITC), similarly to FRET, can be used for 
gaining further information regarding known interactions. ITC is a widely 
applied technique for obtaining thermodynamic information about two interacting 
partners, affording the determination of stoichiometry, ∆ܩ୆଴, ∆ܪ୆଴, and ∆ܵ୆଴ 
(Perozzo et al. 2004). Downsides of the ITC method are the requirement of 
large amounts (more than nanomoles) of reagents and its inaccuracy if 
determining very strong interactions (<10 nM) (Wiseman et al. 1989). 
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3. AIMS OF THE STUDY 
Protein kinases, as well as protein-protein interactions, participate in almost 
every aspect of intracellular signaling. It is therefore well known and 
understandable that aberrant functioning of protein kinases may lead to a 
plethora of diseases, many of which tend to be difficult to alleviate or cure. 
Nevertheless, the research to modulate the activity of known disease-related 
protein kinases is intensifying and drug discovery process can benefit from 
novel sophisticated assays and strategies. 
This study focused on the development and characterization of biligand-
derived photoluminescence probes for highly sensitive assays for basophilic 
protein kinases. The main tasks that were addressed in the present study were 
the following: 
• Application of protein kinase binding-responsive ARC-Lum(Fluo) probes 
for analysis of the binding kinetics of inhibitor:protein kinase complexes. 
• Construction of high-affinity bifunctional ARC-type inhibitors by reference 
to results of extensive structure-affinity studies and X-ray analysis of 
ARC:protein kinase co-crystals. 
• Application of bifunctional ARC-type inhibitors for disruption of strong 
protein-protein interactions. 
• Clarification of the competitive ligand-facilitated dissociation mechanism of 
the bimolecular complex between a bifunctional ligand and protein kinase. 
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4. MATERIALS AND METHODS 
4.1. Binding and displacement assays 
4.1.1. Time-resolved measurement of luminescence intensity 
Time-resolved (TR) measurement of luminescence was performed in an assay 
buffer (if not noted otherwise) consisting of 50 mM HEPES hemisodium salt 
(Sigma or Santa Cruz) (pH = 7.5), 150 mM NaCl (Riedel-de Haën), 0.5 mg/mL 
BSA (Sigma), 5 mM dithiothreitol (Sigma), and 0.005% P20 polysorbate 
(Sigma) with final sample volume of 20 µL. Biochemical measurements for 
obtaining the activity of protein kinases and the affinities of competitive 
inhibitors were conducted on black nonbonding 384-well microplates (round-
bottom low-volume wells, codes 3676 or 4514). The microplates and sample 
solutions were preincubated and measured at 30 °C. 
PHERAstar platereader (BMG Labtech) was used for measurement of 
luminescence intensity. Optical modules HTRF 802D1 [EX 337(50) nm, EM 
675(50)/620(20) nm] or TRF 904B1 [EX 337(50) nm, EM 590(50)/545(10) nm] 
were used to filter out respective wavelengths. The luminescence signal was 
registered in time-gated mode (60 µs delay time after irradiation, 150 µs or 
400 µs intensity acquisition interval).  
The concentration of the active protein kinase was determined by preparation 
of two- or three-fold dilution series of protein kinase and the addition of 
luminescent probe [ARC-Lum(Fluo)] at fixed concentration in the assay buffer 
(binding assay). Luminescence intensity was measured after incubation for 15 
min and results were fitted in GraphPad Prism 5.0 (GraphPad Software) with 
non-linear regression (Equation 4). 
 
ܮܫ = ܤ +ܯ ൣܮ + ܭୈ + ݇ܧ଴ − ඥሺܮ + ܭୈ + ݇ܧ଴ሻ
ଶ − 4ܮ݇ܧ଴൧
2  
 
Equation 4. E0, nominal total concentration of the protein kinase; LI, luminescence 
intensity at E0; B, background signal; M, molar luminescence intensity of ARC-Lum(Fluo) 
in complex with protein kinase; L, total concentration of ARC-Lum(Fluo); KD, 
equilibrium dissociation constant between ARC-Lum and protein kinase; k, the ratio of 
active concentration to the nominal concentration of the protein kinase. 
 
The affinity of competitive inhibitor was determined by preparation of three-
fold dilution series of the inhibitor and addition of fixed concentration of a 
complex between protein kinase and ARC-Lum(Fluo) (displacement assay). 
Luminescence intensity was measured after incubation for 60 min and the 
results were fitted to a sigmoidal dose-response model. The resulting IC50 
values were used to calculate displacement constants (Kd) according to Equation 
5 (Nikolovska-Coleska et al. 2004). 
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ܭୢ =
[ܫ]ହ଴
[ܮ]ହ଴ܭୈ +
ܧ଴ܭୈ + 1
 
 
Equation 5. [I]50, the concentration of free inhibitor at 50% of displacement; [L]50, the 
concentration of free ARC-Lum at 50% of displacement. 
 
 
4.1.2. Förster-type resonant energy transfer (FRET) 
Chinese hamster ovary (CHO) cells stably expressing C-terminally CFP-fused 
PKArIIβ and C-terminally YFP-fused PKAcα (C9H6) (Zaccolo et al. 2000; 
Lissandron et al. 2005) were seeded and grown for up to 72 h on a 6-well cell 
culture plate (Thermo Scientific, code 130184). Cell lysis was performed in NP-
40 lysis buffer (Life Technologies, code FNN0021) in the presence of 1X 
protease inhibitor cocktail (Roche, Complete EDTA-free), 0.5 mM dithiothreitol, 
1% Triton-X, and 0.5 mM phenylmethanesulfonyl fluoride. The approximate 
concentration of fused proteins in the cell lysate was estimated by the intensity 
of fluorescence in comparison to Alexa Fluor 488-conjugated ARC-679. 
Solutions of inhibitors ARC-1411, ARC-902, and PKAc activator cAMP 
were prepared in three-fold dilution series in assay buffer without 5 mg/mL 
BSA. CHO cell lysate was added to a final dilution of 5% (n = 2). Fluorescence 
intensity was measured after 1 h incubation period at 30 °C using PHERAstar 
platereader and the optical module FI608A [EX 427(10) nm, EM 
530(10)/480(10) nm]. The relative fluorescence intensity ratio (FIr) was 
calculated from the results according to Equation 6. 
 
ܨܫ୰ =
		ܫୟ		
			ୢܫ 		 /
	ܫୟ,ୈ	
		ୢܫ ,ୈ		 
 
Equation 6. Ia, emission intensity in the acceptor channel; Id, emission intensity in the 
donor channel in the absence of a competitor, and Ia,D and Id,D are the emission intensity 
in the acceptor and donor channel in the presence of the competitor, respectively. The 
concentration-dependent profile of FIr was fitted to a sigmoidal dose-response model to 
find IC50 values.  
 
 
4.2. Thermal shift assay 
Thermal shift assay was performed in a buffer composed of 50 mM Tris (pH = 
7.5) and 50 mM NaCl with a final sample volume of 25 µL. Protein kinase 
solutions were used at a fixed total concentration of 10 µM in the presence of 
Sypro Orange (90-fold dilution from 5000X DMSO stock, Thermo Scientific, 
code S-6650) with or without (control) 40 µM inhibitor. Samples were 
measured on Multiplate low-profile 48-well unskirted PCR plates (BioRad) 
covered with Microseal C Optical seals (BioRad) in MiniOpticon RT-PCR 
system (BioRad). The thermostat block was cooled to 5 °C and temperature 
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gradient was initiated with heating 1 °C/s up to 90 °C. The temperature gradient 
was accompanied with 0.3 s measurement intervals, in which samples were 
irradiated at 530 nm and the fluorescence intensity was registered at 560 nm. 
The resulting fluorescence intensity data was analyzed with Opticon Monitor 
software (BioRad). Protein melting temperature was determined as the highest 
ratio of ∆ூ∆் during the temperature gradient, and confirmed by fitting the 
fluorescence intensity to the Boltzmann sigmoidal model (Equation 7): 
 
ܨܫ = ܫ୫୧୬ +
ܫ୫ୟ୶ − ܫ୫୧୬
1 + ݁ ఱ்బି்௔
 
 
Equation 7. FI, fluorescence intensity at temperature T; Imin, fluorescence intensity at a 
lower plateau; Imax, fluorescence intensity at a higher plateau; T50, the half maximal 
temperature of protein denaturation; a, slope tangential to the curve at T50. 
 
 
4.3. Dissociation kinetics assays 
The kinetic characterization of dissociation of the complex of a protein kinase 
and ligand was performed in assay buffer (3.1.1.) on black round-bottom low-
volume nonbonding 384-well microplates (code 3676 or 4514). The con-
centrations of ligands were determined spectrophotometrically using NanoDrop 
2000c (Thermo Scientific) and concentration of the active form of protein 
kinase was determined as described in 3.1.1. All reagent solutions, spectro-
fluorometer, microplate, and pipette tips were preincubated at 30 °C on micro-
plate thermostat (Thermo Scientific). Depending on the fluorescent reagent 
used, HTRF 802D1 [EX 337(50) nm, EM 675(50)/620(20) nm], TRF 904B1 
[EX 337(50) nm, EM 590(50)/545(10) nm], or FI608A [EX 427(10) nm, EM 
530(10)/480(10) nm] optical module was employed for registration of the signal 
intensity. 
Two assay setups were used: the intensity decay of fluorescent complex was 
monitored by the addition of competitive inhibitor or non-fluorescent complex 
was disrupted by ARC-Lum(Fluo) probe and intensity increase was monitored. 
10 µL solution of the competitive ligand was mixed with 10 µL solution of the 
complex on microplate at t = 0 and the signal intensity was registered in time 
with 5–60 s intervals. The resulting signal profile was analyzed with Equation 
8A to find koff. Equation 8B was subsequently used where necessary to correct 
the residence time (τ) for incomplete dissociation of the initial complex. 
 
     A      B 
        ܫ = ݁ି௞౥౜౜	∙	௧൫ܫ଴ − ܫ୮୪ୟ୲ୣୟ୳൯ + ܫ୮୪ୟ୲ୣୟ୳             ߬ = ଵ௞౥౜౜	∙಺బష಺౦ౢ౗౪౛౗౫಺బ
 
 
Equation 8. A) I, signal intensity at timepoint t; I0, initial signal intensity; Iplateau, signal 
intensity at equilibrium. B) τ, the residence time of complex corrected according to 
incomplete dissociation. 
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4.4. Isothermal titration calorimetry 
Untagged full-length human PKAc (UniProt accession no. P17612) was 
expressed in Escherichia coli BL21-(DE3) cells (Stratagene) from a construct 
based on the vector pET-28b(+) (Novagen) in Studier autoinduction medium. 
PKAc was purified as described previously (Engh et al. 1996). PKAc samples 
were previously dialysed overnight at 4 °C against buffer comprising 75 mM 
Tris (pH 7.5) and 20 mM NaCl using SnakeSkin dialysis tubing (Thermo 
Scientific, cut off: 10 000 MW), and concentrated by using a spin-column 
(MilliPore, 5 mL, cut-off: 10 000 MW) at 4000 RPM. Isothermal titration 
calorimetry (ITC) was performed using a low-volume ITC200 (MicroCal). 
Titrations were performed by injecting 20 consecutive aliquots (1.6 µL) of 
ligand solution (200 µM) into the ITC cell containing PKAc (20 µM) at 30 °C. 
The samples were stirred at 410 RPM. Twenty injections were separated by 
150 s of equilibration. MicroCal ITC200 control software (v 1.26) was used for 
experiment design and the data were fitted using MicroCal ITC200 Analysis 
Software (v 7.2).  
30 
5. SUMMARY OF RESULTS AND DISCUSSIONS 
5.1. Development and validation  
of photoluminescence-based assays (Papers I and III) 
5.1.1. Discovery of long-lifetime luminescence  
of ARC-Lum probes 
The literature review adverted to the importance of protein kinases in cellular 
signaling and their role in diseases. The conserved structure of kinase domain 
allowed the identification of 518 genes coding protein kinases in the human 
genome (Manning et al. 2002). Many signaling pathways have been established, 
however, cross-talk between the pathways complicates comprehensive under-
standing of the contribution of individual protein kinases. Reliable methods are 
still needed for monitoring the cellular activity of protein kinases and determi-
nation of inhibitory potency of compounds in cells. The enzymatic property of 
protein kinases has enabled the development of various assays based on 
inhibition of phosphorylation reaction for characterization of ligands (Zhang et 
al. 2015; Stenroos et al. 1998; Rininsland et al. 2004).  
The extensive structure-activity studies and X-ray analysis of ARC:PKAc 
co-crystals have supported the construction of bifunctional inhibitors possessing 
sub-nanomolar affinity towards PKAc (Lavogina et al. 2009). Functionalization 
of ARCs with fluorophores resulted in high-affinity fluorescence probes (ARC-
Fluo probes). The comparison between FA-based binding assay with con-
ventional substrate phosphorylation assay gave an excellent linear relationship 
between Kd and IC50 values (Vaasa et al. 2009). The sub-nanomolar affinity of 
ARC(Fluo) fulfilled important requirements for an effective application in FA-
based assays for analysis of protein kinases: the required concentration of an 
analyte for anisotropy change can be small and only active fraction of the 
protein kinase is detected, as the probe binds selectively to a catalytically active 
form of the enzyme. Unfortunately, anisotropy-based assays are sensitive to 
non-specific binding, restricting their use in crude lysate samples and for 
cellular applications. 
A homogeneous method based on TR measurement of FRET efficiency has 
been demonstrated by using europium (Eu) cryptates as FRET donors in 
combination with fluorescent proteins as acceptors (Bazin et al. 2001). Eu-
cryptate emission spectra are characterized by narrow peaks, allowing the 
performance of measurement at wavelengths where only the acceptor emits. 
This technique eliminates many shortcomings of FA and FRET assays by 
filtering out the auto-fluorescence of the sample, drastically reducing non-
specific interferences and permitting measurements in crude samples. However, 
the drawbacks of the assay are the need for the antibody, derivatization of the 
substrate with biotin and fluorescent protein with streptavidin. Further 
developments led to inhibitors functionalized with an organic dye, removing the 
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need for the labelled substrate, while His-tagging of the protein and anti-His 
antibody were still needed (Figure 1A) (Lebakken et al. 2009). 
Next, ARC-type probes were constructed for the development of a TR-FRET 
assay for analyzing protein kinases. ARCs possessing sub- to low nanomolar 
affinity towards many basophilic protein kinases constitute a set of binders 
whose derivatization with fluorophores leads to fluorescent probes for the 
construction of generic binding assays exploring low concentration of the probe 
and kinase. An ARC-inhibitor comprising 5-(2-aminopyrimidin-4-yl)thiophene-
2-carboxylic acid (AMTH) within ATP-competitive moiety was synthesized 
and the terminal lysine was conjugated with Alexa Fluor 647 dye (ARC-1063). 
Anti-His antibody was labelled with Eu-cryptate and His-tagged protein kinase 
was used as the target. It was expected that upon excitation at 337(50) nm, the 
increase in long-lifetime luminescence at 670(50) nm is registered upon 
formation of the ternary complex. In the course of the measurements, titration 
of ARC-1063 with protein kinase increased long-lifetime luminescence signal 
in a concentration-dependent manner even in the absence of the donor, Eu-
cryptate-comprising anti-His antibody (Figure 1B).  
 
 
Figure 1. The difference between antibody:fluorescence ligand and ARC-Lum based 
homogeneous TR-FRET assays. A) FRET from the Eu-labeled antibody and fluorescence 
probe (FL) increases in ternary complex with a protein kinase (PK), accompanied by a 
decrease in the donor emission intensity (620 nm) and increase in the acceptor's emission 
intensity (675 nm). B) Excitation at 337 nm leads to long-lifetime luminescence intensity 
only if ARC-Lum probe is bound to a protein kinase. 
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Long-lifetime luminescence was characteristic for the complex of ARC-1063 
with protein kinases PKAc, MSK1, ROCKII, PKBγ, PKGIα, and PKCδ, while 
in the absence of protein kinase the TR signal of luminescence of ARC-1063 
was negligible (Paper I Figure 2A). A similar phenomenon was present with 
ARCs comprising 5-(2-aminopyrimidin-4-yl)selenophene-2-carboxylic acid 
(AMSE) within ATP-competitive moiety (ARC-1139). Furthermore, the heavy 
selenium atom induced greater long-lifetime luminescence intensity compared 
to sulfur-comprising π-conjugated fragment, and in parallel, shorter lumi-
nescence lifetime (Paper I Table 1). Titrating the complex of protein kinase and 
ARC-1063 or ARC-1139 with competitive inhibitor resulted in the concent-
ration-dependent displacement of the probe, verifying the binding-responsive 
character of these probes. A novel property of organic long-lifetime lumi-
nescence probes was discovered and AMTH- or AMSE-comprising ARC-Lum 
probes (Figure 2) were introduced. 
 
 
 
Figure 2. The structure of bifunctional probe ARC-1063. AMTH- or AMSE-comprising 
ATP-competitive moiety acts as an intramolecular, long-lifetime luminescence donor to 
the fluorescent dye. 
 
The long-luminescence lifetime of ARC-Lum probes upon binding into the 
active site of protein kinase was attributed to the burial and fixation of the 
structure of ATP-competitive moiety into a deep hydrophobic pocket, which 
accompanies reduced quenching from dissolved oxygen species. Irradiating 
bound ARC-Lum excites the electron within AMTH- or AMSE-conjugated 
system (donor) into higher singlet energy state and allows internal energy 
conversion to the excited triplet state (Paper I Figure 1). The resonant energy 
transfer from excited triplet state of the donor to the excited singlet energy state 
of fluorescent dye (acceptor) is kinetically delayed, resulting in a long lifetime 
of emission and amplification of emission intensity as the quantum yield (QY) 
of the donor is low compared to the QY of the acceptor. This physical pheno-
menon is researched and discussed in detail in further studies (Ligi et al. 2016). 
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5.1.2. Application of ARC-Lum probes in biochemical assay 
The growing drug industry focusing on protein kinases and their inhibitors 
benefits from robust, reliable, and rapid assays for screening of large compound 
libraries. Sensitive binding and displacement assays based on ARC-Lum probes 
allow the usage of minute amounts of both, protein kinase and probe, excluding 
the need for antibodies or substrates and drastically reducing the time needed 
for analysis. 
Several ARC-Lum probes have been synthesized for analysis of protein 
kinases (Paper III, Table 1). The application of probe ARC-1182 was further 
characterized in a displacement assay with PKAc and competitive inhibitors to 
provide additional information on planning optimal conditions of the 
experiment. The low-picomolar affinity (Kd = 20 pM) of ARC-1182:PKAc 
complex in combination with TR measurement of luminescence (TRL) intensity 
allows the determination of affinities of competitive inhibitors in a wide range. 
The possibility to employ ARC-Lum in high excess compared to the protein 
kinase without an increase in the non-specific signal enables the determination 
of 30-fold higher inhibitor affinities than that of the probe. The lowest 
resolvable affinity is determined by the solubility. Data analysis according to 
the classical Cheng-Prusoff equation (Cheng and Prusoff 1973) would result in 
values delineating from regression and is not applicable in the case of tight-
binding inhibitors (Paper III Graph 5). Instead, the modified equation 
accounting the concentration of free inhibitor ([I]50), not the total concentration 
of inhibitor (IC50) should be used (Equation 5) (Nikolovska-Coleska et al. 
2004). It was proposed that the limit of the resolvable range of affinities should 
be calculated at the point where [I]50 = ½[E]T. In the presence of the highest 
concentration of probe ARC-1182 used (C = 80 nM) at 0.5 nM concentration of 
PKAc, the highest affinity of competitive inhibitor towards PKAc that can be 
determined is 60 fM (Paper III Graph 5 blue solid line). Decreasing the 
concentration of ARC-1182 to 0.5 nM, as low as 1 mM affinities of inhibitors 
are possible to resolve, which in practice can be limited by the insolubility of 
the inhibitors. Similar modeling of a resolvable range of affinities of a 
competitive inhibitor for specific probe:protein complex supports the selection 
of concentrations for acquiring a well-resolved and accurate displacement 
curve, as well as aiding the selection of the probe with an optimal affinity for a 
specific purpose. 
Screening large libraries of compounds for finding a lead compound can be 
a highly time-consuming and costly process. The search for novel lead scaffolds 
usually begins with in silico mining from tens of thousands to millions of 
structures (Gong et al. 2016). Hundreds of compounds can be selected for 
biochemical characterization. Initial hit identification immensely speeds the 
process of finding potent lead compounds. This can be achieved by measuring 
the decrease percentage of the signal of the probe:target complex induced by a 
single concentration of competitive inhibitor (one-point analysis) and 
calculating the estimated IC50 by Equation 9. Estimation of IC50 from one-point 
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analysis correlates well with IC50 from the full displacement curve (Paper III 
Graph 8) in case the value of the measured point falls into the linear range of 
displacement. The linear range falls into the region 0.1IC50<ICx<10IC50, where 
ICx corresponds to the concentration of inhibitor at which x % of TRL intensity 
is remained (Copeland 2013). 
 
ܫܥହ଴ =
ܫܥ୶
100
x − 1
 
 
Equation 9. IC50, inhibitor concentration at the half-maximal signal; ICx, inhibitor 
concentration at which x % of the signal is retained. 
 
TRL-intensity assay based on the application of ARC-Lum probes serves as an 
efficient method for initial hit screening. Manual pipetting, incubation, and 
measurement of 384-well plate can highlight promising lead compounds within 
1 hour. For comparison, SPR measurement for initial evaluation of 278 com-
pounds needs 3 minutes per compound for a measurement cycle and a total of 
14 hours for measurements, not including the time needed for the surface 
regeneration of the chip (Miura et al. 2016). The automated ARC-Lum-based 
assay is up-scalable to the 1536-well plate while retaining the short 
measurement time. 
 
 
5.1.3. Application of ARC-Lum(Fluo) probes for cellular studies 
The binding-responsive intramolecular TR-FRET property of ARC-Lum probes 
offers a unique possibility to monitor the activity of protein kinases in live cells 
and cell lysates without the need for labelling of proteins. The cell plasma 
membrane-penetrating property of hexa-arginine-comprising ARCs has been 
established, excluding the need for conjugation of the compound with additional 
transport vectors (Uri et al. 2002). 
Genetically unmodified human embryonic kidney cells (HEK293) were 
incubated with the solution containing the ARC-Lum probe ARC-1139 (C = 
10 μM). The intracellular localization of ARC-1139 was monitored with a 
fluorescence microscope: ARC-1139 quickly crossed cell plasma membrane, 
distributed into the cytoplasm and concentrated into special regions of nuclei, 
apparently nucleoli (Paper I Supplementary Figure 10). 
Subsequently, C9H6 cells were supplemented with Forskolin in the presence 
of ARC-1139. FRSK activates AC and consequently, PKA. The released 
catalytic subunit PKAc of PKA interacts with the probe ARC-1139 leading to 
increase in long-lifetime luminescence intensity signal that was registered with 
PHERAstar luminescence platereader (Figure 3). An ATP-competitive inhibitor 
H89 was introduced after signal stabilization. H89 crosses cell plasma 
membrane and binds to PKAc with relatively high selectivity and affinity. H89 
disrupted the complex between PKAc and ARC-1139, resulting in loss of long-
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lifetime luminescence intensity. Furthermore, H89 reduced the luminescence 
intensity compared to its initial value. Thus ARC-Lum probes demonstrated the 
usability as intracellular sensors for monitoring real-time changes in the 
concentration of protein kinases in response to extracellular stimuli. 
 
 
 
 
5.2. Structure-affinity and X-ray crystal  
structure studies of bifunctional inhibitors  
(Paper I, Paper II, unpublished results) 
A new set of compounds was synthesized proceeding from results of crystal 
structure analysis of ARC-670:PKAc co-crystals (Pflug et al. 2010). Replacing 
the structure of ATP-competitive moiety of ARC-670 with 7-deazapurine led to 
the high affinity of the compounds, this property was subjected to further opti-
mization. The potential of varying the length of α,ω-diacid linker was realized 
and the biochemical analysis of protein kinases PKAc, PKBγ, and ROCK2 
showed that the optimal distance between the nucleoside-mimicking and 
peptide moieties was achieved by using α,ω-nonanedioic acid as the linker 
(Paper II, Table 1). This design led to the binder revealing the highest affinity 
towards PKAc to date, ARC-1411 that possesses one-digit picomolar Kd value 
(Kd,PKAc = 3 ± 1 pM). At 1 µM concentration ARC-1411 inhibited many other 
basophilic protein kinases by more than 90% as tested in a commercial panel of 
protein kinases (Paper II Table S1).  
The inhibitory potency (IC50) of compounds in the phosphorylation reaction 
has been shown to correlate well with their affinity determined in a binding 
assay with FA (Vaasa et al. 2009) or TRL intensity readout (Paper I Figure 3A). 
Next, the thermal shift assay based on a comparison of the protein denaturation 
temperature with and without the presence of an inhibitor was conducted. ARC-
type inhibitors strongly stabilized the structure of PKAc: compounds with low-
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Figure 3. Real-time monitoring of PKA activity in living C9H6 cells after loading the 
cells with ARC-1139: time points of addition of Forskolin (FRSK, 25 μM) and 100 µM 
(green ●) or 10 µM (purple ■) H89 are marked with the arrows. 
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picomolar affinity shifted the denaturation temperature of PKAc from 42 °C to 
more than 58 °C (ΔTm = 16 °C). Kd values obtained from TRL intensity based 
assay for 7-deazapurine-comprising ARCs correlated well with the ΔTm values 
found from the thermal shift assay (Figure 4A, black data points, R = 0.97). 
ARC-inhibitors comprising different ATP-competitive moieties induced 
stronger thermal stabilization effect for inhibitors possessing equal or lower 
affinity (Figure 4A, blue data points). Therefore, the linear relationship between 
the logKd and ΔTm values holds better for inhibitors taking part in similar 
interactions or inducing similar conformational changes in the structure of the 
protein. The latter is evident from the crystal structure analysis of ARC-
1411:PKAc co-crystal compared to that of ARC-1408 (PDB ID: 5IZF) or ARC-
1416 (PDB ID: 5J5X) co-crystals. The –(D-Arg)6–D-Lys–NH2 peptide moiety 
attached to α,ω-nonanedioic acid in ARC-1411 sterically hinders the overall 
optimal positioning and interaction of the second Arg residue with the protein, 
directing it out towards the water environment and forcing the Gly-rich flap of 
PKAc into an open conformation (Paper II Figure 5B, Figure S7). In contrast, 
two Arg residues separated by the linker in ARC-1408 and Ala replacing α-Arg 
in the structure of ARC-1416 allow the adaption of the Gly-rich flap of PKAc 
the intermediate conformation (Paper II Figure 5B). The difference of open 
and intermediate conformations is the main reason why ARC-1416 stabilizes 
the structure of PKAc to a greater extent relative to its affinity compared to 
ARC-1415 (structure of ARC-1411 without terminal Lys) and ARC-1411 
(Figure 4A). The measurements with PKBγ did not result in good linear 
correlation, as the PKBγ was not activated by phosphorylation at Thr 309, 
whereas the similar trend of increase in ΔTm with an increase in affinity of 
respective ARC was evident (Figure 4B). 
 
A         B 
  
 
Figure 4. Correlation of thermal shift assay results (ΔTm) with affinities (negative 
logarithm of Kd) measured with TRL-intensity assay for PKAc (n = 6) (A) and PKBγ (n = 3) 
(B). ARC-668, ARC-902, ARC-903, and ARC-1102 affinities found or calculated from 
literature (Lavogina et al. 2010b; Vaasa et al. 2009). 
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No PKB isoforms have been co-crystallized with ARCs and the exact 
positioning of the bifunctional inhibitor in the active site of PKBγ is unclear. 
Compared to PKAc, the thermal shift of PKBγ in the presence of ARC-1416 or 
ARC-1415 gave a better correlation with their measured affinities, suggesting 
that sequential D-Arg residue continuing from the linker are favored in terms of 
their placement. Further increase in affinity can, therefore, be achieved by 
replacing β-Arg in the structure of ARC-1411, possibly leading to sub-
picomolar Kd values towards PKAc. 
Isothermal titration calorimetry is continually a method of choice for gaining 
direct thermodynamic data (∆ܩ୆଴, ∆ܪ୆଴, ∆ܵ୆଴) regarding the binding between 
proteins or the protein and a ligand. These parameters were investigated for 
ARC-1404, ARC-1409, or ARC-1411 binding to PKAc (Figure 5). Binding of 
each ligand to PKAc possessed high value of ∆ܪ୆଴, driven by polar interactions 
between the ligand and protein. The length of α,ω-nonanedioic acid linker 
within structures of ARC-1409 and ARC-1411 resulted in superior enthalpy 
term compared to ARC-1404 comprising α,ω-octanedioic acid linker. The 
insufficient length of the linker within ARC-1404 is possibly prohibiting the 
interaction between an Arg residue and Asp167 that is present in the crystal 
structure of ARC-1408, comprising an α,ω-nonanedioic acid linker. The term 
∆ܵ୆଴ was relatively large, especially for ARC-1409 and ARC-1411, resulting 
from tight fixation of the flexible structure of both ARC and PKAc upon 
association. Introducing a rigid structural fragment, for example by replacing  
β-Arg within ARC-1411 may reduce entropic gain from binding to PKAc and 
further improve the affinity. Despite useful thermodynamic data, ITC requires 
magnitudes higher concentration of reagents and is known to be inaccurate in 
determining high-affinity interactions by binding (Leavitt and Freire 2001). 
 
 
 
Figure 5. ITC binding isotherms for ARC-1404 (A), ARC-1409 (B), and ARC-1411 
(C) with PKAc (n =1). 
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5.3. Bifunctional inhibitors as disruptors of PPIs (Paper II) 
HTS of compound libraries, fragment-based drug design, and virtual screening 
are primarily limited to the detection of PPI inhibitors with affinities in the 
micromolar range (Nim et al. 2016), whereas inhibitors with higher affinity are 
required for successive disruption of tight-binding PPIs with KD values below 
200 nM. An inhibitor disrupting the PPI in a biochemical assay may fail in cells 
either due to insufficient cellular translocation of the inhibitor, degradation of 
the inhibitor in biological milieu, or due to the reinforcement of PPI in the 
complex cellular environment. 
The concept of applying bifunctional inhibitors for disruption of strong PPIs 
was studied on PKA holoenzyme with ARC-type inhibitors. The subunits of 
PKA, PKAr and PKAc interact at protein substrate intraface of PKAc and are 
held together by the interaction with KD value of 100 pM (Cheung et al. 2015). 
Disruption of this interaction directly by a reversible inhibitor at the protein 
substrate binding site needs a molecule with an impressive affinity that is 
unlikely to be achievable due to the nature of PPI intraface. Therefore, we 
employed ARCs that bind simultaneously to two substrate sites of PKAc – 
ATP-competitive moiety of the inhibitor enforces the interaction and protein 
substrate-competitive moiety disrupts the PPI between PKAc and PKAr. 
First, ARC-1413, a 5-TAMRA-labelled probe (Kd,PKAc = 5 pM) was used in 
FA-assay to detect the displacement by protein substrate competitive inhibitor 
PKArI or PKI (Paper II Figure 2). In comparison to the sub-nanomolar 
inhibitor ARC-902 (Kd,PKAc = 0.33 nM) both PKArI and PKI displaced ARC-1413 
with lower IC50 value. The addition of cAMP (50 µM) to the series containing 
PKArI resulted in the reformation of ARC-1413:PKAc complex (FA restored to 
the value of full complex), indicating that displacement was due to a specific 
interaction between PKArI and PKAc. 
Next, a genetically engineered variant of PKA, cells expressing fusion 
proteins of PKA subunits with fluorescent proteins, was used as a cAMP sensor 
based on the measurement of the intensity of FRET between two fluorophores 
positioned in close proximity. The sensor was used to gain direct evidence that 
ARC-type high-affinity bifunctional ligands disrupt the interaction between 
regulatory and catalytic subunits of PKA. Lysate of C9H6 cells stably expressing 
the fusions of cyan fluorescent protein (CFP) and yellow fluorescent protein 
(YFP) with PKAr and PKAc (CHO cells stably expressing fusion proteins 
PKArIIβ-CFP and PKAcα-YFP), respectively, was separated and diluted 20-
fold. The dilution series of ARC-1411 or ARC-902 disrupted the interaction of 
PKArIIβ-CFP:PKAc-YFP in the lysate, indicated by the decrease in FRET ratio 
(EX 427 nm, EM 530/480 nm) (Paper II Figure 3B). IC50 values for 
displacement of PKArIIβ from the PKA holoenzyme were 2 nM and 109 nM in 
the presence of ARC-1411 (KD,PKAc = 3 pM) and ARC-902 (KD,PKAc = 0,33 nM), 
respectively. In comparison, the disruption of PKA holoenzyme by cAMP 
resulted in an EC50 value of 48 nM, showing the high potency of ARC-1411 for 
disruption of the PKA holoenzyme. 
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It was not known whether H89 (Hidaka et al. 1990), a generic inhibitor of 
AGC-group protein kinases (KD,PKAc = 10 nM) (Viht et al. 2007) could bind into 
the ATP-pocket of PKAc in the tetrameric PKA holoenzyme. The effect of H89 
on PKA holoenzyme was investigated using the lysate of C9H6 cells 
constituting fluorescent fusion proteins PKArIIβ-CFP and PKAcα-YFP. The 
titration series of H89 revealed that H89 did not disrupt PKA holoenzyme at 
concentrations up to 10 µM (Figure 6B). The PKA holoenzyme in 5% C9H6 
cell lysate was disrupted by 1 µM ARC-902, resulting in cessation of FRET 
between fluorescent proteins and, consequently, disruption of the PKA tetramer 
(Figure 6B). In presence of 1 µM ARC-902, H89 displaced ARC-902 at higher 
concentrations and lead to recurrence of FRET, indicating reformation of the 
PKA holoenzyme (Figure 6A, Figure 6B). Interestingly, in the course of 
binding to the hydrophobic pocket of PKAc, H89 did not induce any detectable 
change in the conformation of the PKA holoenzyme according to FRET ratio 
(Figure 6C). However, only total disruption of the PKA holoenzyme can be 
excluded, as the distance between fused fluorescent proteins did not change and 
the conformational shifts within immediate proximity to the active site cannot 
be ruled out.  
 
 
 
Figure 6. FRET assay for PKA holoenzyme dissociation. (A) Scheme of the proposed 
process of displacement of a PKArIIβ-competitive bisubstrate probe ARC-902 (black) 
from PKAcα (orange) by H89 (green), leading to PKA holoenzyme reformation and 
accompanying an increase in FRET from CFP to YFP. (B) Dilution series of H89 in the 
absence (red ●) and presence (blue ■) of 1 μM ARC-902. (C) Dissociation kinetic 
profiles of PKArIIβ-CFP:PKAcα-YFP with the addition of ARC-902 (10 μM, blue ■) or 
H89 (50 μM, red ●) at t = 0. 
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This result points to a fundamental difference between mono- and bifunctional 
ligands for inhibition of PKAc in intracellular milieu. H89, staurosporine, and 
other ATP-competitive inhibitors do not discriminate between PKAc-bound and 
free PKAc subunits, they can associate with PKAc in both states of the latter 
protein. Bifunctional inhibitors compete with PKAr for binding to PKAc, 
preferably interacting first with free subunits of PKAc to satisfy equilibrium 
conditions. At higher concentrations, bifunctional inhibitors disrupt the PKA 
holoenzyme and relocate PKAc away from the cell membranes where PKAr 
molecules are bound via interactions with AKAPs. Monofunctional inhibitors 
do not disrupt the PKA holoenzyme and the escape of monofunctional inhibitor-
bound PKAc occurs only after binding of cAMP molecules to the PKAr dimer 
of the PKA holoenzyme. Considering that numerous AKAPs scaffold both AC 
and PKA (Dessauer 2009) proteins, the application of ARCs emerges as a novel 
tool for studying the underlying mechanism of this important signaling pathway. 
The successful application of ARCs for disruption of the PKA holoenzyme 
led to the conception of employing bifunctional ligands for disruption of strong 
PPIs. According to this approach, one of the moieties of the bifunctional ligand 
competes with the partner protein for the interactions in the “hot spot” interface 
area of a protein, while the other moiety reinforces the interaction by occupying 
a well-defined binding site (i.e. the hydrophobic pocket). A key factor for 
achieving optimal binding of a bifunctional ligand to the target protein is the 
length of linker fragment. In the current work, this was achieved by utilizing an 
α,ω-diacid linker, which allowed the atom-wise fine-tuning of the distance 
between two moieties, improving the affinity 17-fold towards PKAc, 10-fold 
towards PKBγ, and 5-fold towards ROCKII (Paper II Table 1, ARC-1409 
compared to ARC-1404). The approach of using a bifunctional ligand and 
employing an “affinity hook” is limited to proteins adjoined by a hydrophobic 
pocket that are participating in PPIs, possibly covering the whole purinome 
composed of 3200 protein members (Ambrosi 2009). Bifunctional inhibitors 
ensure the disruption of targeted PPI at lower concentrations due to their high 
affinity (i.e. ARC-1411). The introduction of such disruptors of PPIs into drug 
development pipelines presumes to bypass the limits of “the Lipinski’s Rule of 
Five”. 
  
 
5.4. Dissociation kinetics assays utilizing ARC-Lum  
probes (Paper I, Paper IV, unpublished results) 
5.4.1. Measurement of dissociation kinetics of ligand: 
protein complex using TRL-based assay 
Information regarding the dissociation rate of a molecular complex is important 
for the construction of a potent inhibitor possessing long residence time. 
Without addressing dissociation kinetics of the ligand:protein complex, highly 
potent lead compounds may be discarded in assays based on the data of KD 
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alone. The main reason for not characterizing dissociation kinetics of a 
molecular complex is frequently the limited number of assays that provide 
reliable data in conjunction with a simple setup of the assay. 
The capability of TRL intensity assay was studied for characterization of 
dissociation kinetics of complexes of PKAc with different ligands (Figure 7). 
This setup is based on mixing a ligand under observation with the target protein 
kinase to achieve the level of >90% bound kinase. Thereafter, ARC-Lum probe 
is added in excess (at 50–300 nM concentration, depending on the affinity of 
the competitive ligand) to achieve complete displacement of the inhibitor under 
study and the TRL intensity is monitored in time. A similar setup utilizing the 
FA readout instead of TRL intensity can only be used in conditions where the 
fraction of free fluorescence probe after displacing the inhibitor is small. The 
association rate of ARC-type bifunctional ligands with PKAc has been shown to 
be diffusion limited (Viht et al. 2007) and the resulting time-dependent increase 
in TRL-intensity characterizes the dissociation rate of ligand in complex with 
PKAc. The found residence time of ARC-583 on PKAc (Table 1) was well 
comparable to the time established previously with an SPR measurement 
(Figure 7A) (Viht et al. 2007). Limited by the equipment (PHERAstar Plus) and 
manual pipetting, the highest measurable koff for the ligand:PKAc complex was 
0.15 s-1, corresponding to the residence time of more than 6 s. Therefore, due to 
their short residence time on PKAc, this assay failed to characterize most of the 
tested ATP-competitive inhibitors except staurosporine, for which TRL signal 
resulted in a resolvable dissociation profile (τ = 20 s). The assay based on TRL 
intensity can be utilized for measuring faster dissociation kinetics by reducing 
the time between mixing and initiation of luminescence intensity measurements 
with the help of a quick dispensing/mixing system (PheraSTAR FL with 
automated injectors) or by the application of a flow equipment. 
  
 
Ligand koff/s-1 (SEM) τ/s 
staurosporine 5.0·10
–2 
(2.5·10–3) 20.0 
ARC-583 1.8·10
–2 
(0.7·10–3) 54.7 
ARC-1041 1.0·10
–2 
(0.3·10–3) 96.6 
ARC-1042 2.8·10
–2 
(0.9·10–3) 35.2 
ARC-1408 1.9·10
–2 
(1.0·10–3) 53.8 
Figure 7. Measurement of ARC-1063(100 nM):PKAc(1 nM) binding by a time-
dependent increase in TRL-intensity, limited by koff of respective inhibitor. A) Kinetic 
profile for dissociation of staurosporine (red ●), ARC-583 (blue ■), ARC-1041 (purple ▲), 
ARC-1042 (green ▼), or ARC-1408 (orange ♦) from the complex with PKAc (n = 2). 
B) Dissociation rate constants (SEM, standard error of the mean) and mean residence 
times (τ) found for the respective ligands on PKAc. 
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The described assay based on TRL intensity measurement offers a rapid homo-
geneous method for characterization of binding kinetics of the compounds. 
Furthermore, combining the method with automated pipetting in TR-capable 
microplate readers and one-point analysis (described in 4.1.2.), multiple essential 
parameters characterizing the thermodynamics and kinetics of association of a 
ligand with the target protein can be extracted simultaneously. 
 
 
5.4.2. Facilitation of dissociation rate of bifunctional  
inhibitor from complex with protein kinase 
Dissociation process of the complex between a ligand and a protein may consist 
of several steps (Vauquelin and Van Liefde 2012). Separation of microscopic 
steps of the process is experimentally difficult and is rarely achieved, macro-
scopic steps involve an overall change in the 3-D structure of the protein 
(induced fit) and subsequent escape of the ligand from the protein. In a simple 
case, the contribution of conformational change in protein to the overall rate of 
dissociation is minute and can be classified as a microscopic event. Regardless 
of the exact mechanism, dissociation of the complex follows the kinetics of the 
first order reaction and the kinetics is independent of the concentration of the 
complex (Pollard 2010). 
The application of ARC-Lum(Fluo) probes for intracellular studies resulted 
in an unexpected kinetic behavior of the probes. The addition of the competitive 
inhibitor H89 induced a faster dissociation of ARC-1139 and PKAc in C9H6 
cells than anticipated, as revealed by the decrease in TRL intensity (Figure 3). 
Subsequent biochemical experiments showed inconsistent koff values for the 
complexes of bifunctional probes and protein kinases.  
The effect of competitive inhibitors on the dissociation rate of molecular 
complexes was investigated on the example of the complex of ARC-1063 and 
PKAc (Paper IV Figure 1). All tested ligands (inhibitors and substrates) 
facilitated the rate of dissociation of ARC-1063:PKAc complex at higher con-
centrations (Figure 8). Thereby, both monofunctional and bifunctional 
inhibitors induced the effect of facilitation towards the rate of dissociation. 
This finding suggested that bifunctional inhibitors possess two macroscopic 
dissociation steps. The results of accelerated dissociation suggested that the 
moiety of the bifunctional ligand directed to the ATP-binding pocket associates 
with and dissociates from the deep hydrophobic pocket with the rate 
(characterized by ka,1 and kd,1, respectively, Figure 9A) similar to that of the 
monofunctional ligand (structurally corresponding to the dissociated moiety). 
The relatively small dissociation rate constants (koff < 0.01 s–1) that are 
characteristic for tight-binding bifunctional molecules (ARC-type inhibitors) 
result from the favorable re-binding of the ATP-competitive moiety due to the 
existence of the second moiety. The second moiety is continuously bound to the 
protein and holds the detached moiety in close proximity to its binding site. 
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Figure 8. Dissociation profile of ARC-1063:PKAc complex initiated by addition of the 
following ligands at t = 0 s. A) Bifunctional inhibitor ARC-1416, concentration range 
1 nM – 5 mM. B) ATP-competitive inhibitor H89, concentration range 1 μM – 1 mM. 
C) Bifunctional inhibitor ARC-902, concentration range 100 nM – 1 mM. D) ATP (in 
the presence of 10 mM Mg2+), concentration range 100 μM – 10 mM. Complex, ARC-
1063:PKAc w/o competitive inhibitor; Dash (-),1 nM ARC-1063. 
 
The large excess concentration of the competitive compound increases the 
probability that the latter molecules occupies the ATP-binding site of the 
protein kinase within the dissociation-association event of an ATP-competitive 
fragment of the bifunctional ligand. The competitive compound (for example, 
ATP) can dissociate quickly, however its high concentration allows another 
molecule to occupy the binding pocket instead of ATP-competitive moiety of 
bifunctional ligand. The re-binding of ATP-competitive moiety of the 
bifunctional ligand is prohibited and subsequent dissociation of the peptide 
moiety is accelerated, leading to facilitated full escape of the bifunctional 
ligand. Herein, the facilitated dissociation rate constant (koff,fac) for the complex 
between a bifunctional ligand and target protein characterizes the rate at an 
infinite concentration of the competitive ligand. For a bifunctional ligand, under 
completely facilitated conditions this leads to dissociation rate constants 
according to the equation ݇୭୤୤,୤ୟୡ = 	 ௞ౚ,భ	∙	௞ౚ,మ௞ౚ,భା	௞ౚ,మ or ݇୭୤୤,୤ୟୡ = 	
௞ౚ,య	∙	௞ౚ,య
௞ౚ,యା	௞ౚ,య, depending 
on the nature of both bifunctional ligand and competitive ligand. In case the 
competitive ligands were applied at concentrations less than 1 μM, the 
dissociation of ARC-1063:PKAc complex showed a plateau of residence time 
values (Paper IV Figure 1D). The upper plateau value of residence time (202 s 
for ARC-1063 on PKAc) designates the intrinsic residence time of the 
bifunctional ligand on protein. The intrinsic residence time (τint) and intrinsic 
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dissociation rate constant (koff,int) characterize the dissociation rate of a complex 
in the absence of a competitive ligand (Figure 9B). Despite that rates of 
individual macroscopic dissociation steps (kd,1, kd,2, kd,3, kd,4) may be relatively 
large (> 0.1 s–1), the re-binding of the dissociated moiety is favored due to 
spatial proximity to the binding site (Vauquelin and Van Liefde 2012), leading 
to formation of full complex by following rate constant ka,1 or ka,3. Intrinsic 
residence time of a bifunctional ligand on protein can be described by rate 
constant ݇୭୤୤,୧୬୲ = 	 ௞ౚ,భ	∙	௞ౚ,మ௞ౚ,భା௞౗,భା	௞ౚ,మ or ݇୭୤୤,୧୬୲ = 	
௞ౚ,య	∙	௞ౚ,ర
௞ౚ,యା௞౗,యା	௞ౚ,ర (Tummino and 
Copeland 2008). 
 
 
 
Figure 9. Facilitated dissociation of the complex of a bifunctional ligand and protein. 
A) Dissociation of the complex between a bifunctional ligand and protein kinase. 
B) The difference between the values of the residence time of higher and lower plateaus 
reveals the total contribution of the fast re-binding event of the detached moiety. koff,int, 
the intrinsic residence time of complex between bifunctional ligand and protein; koff,fac, 
 
The facilitation of dissociation rate was evident from 1 µM to over 10 µM 
concentration of displacing compound and revealed the dependence on the 
structure of ATP-competitive moiety (Paper IV Figure 1B, Figure 1D). ARC-
1416 [comprising 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine] and H89 
{N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide} facilitated 
the dissociation of ARC-1063:PKAc at lower concentrations compared to ATP 
and ARC-902 (comprising adenosine). This difference from the structure of 
competitive inhibitor arises from their association rates with PKAc, wherein 
slower associating compounds require a higher concentration to increase the 
probability of occupying vacated ATP-binding site by bifunctional ligand. 
Two molecular interaction mechanisms were found that could explain the 
phenomenon of facilitated dissociation. First, the effect is similar to the 
proposed model of rapid re-binding, in which the dissociation of two molecules 
is followed by fast association, as the molecules continue to reside within close 
proximity (Paramanathan et al. 2014). In the presence of high concentration of 
competitive ligand, the re-binding event is prevented in a concentration-
dependent manner due to the occupation of the site by the competing ligand. 
the facilitated residence time of complex. 
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Second, the dissimilar facilitated rates by different structures (Paper IV Figure 
1D) of competitive ligands indicate the formation of the ternary complex 
(Figure 10), as the association rates of competitors have a significant effect, 
contrary to the model of rapid rebinding, and the discovered effect of 
facilitation was several folds stronger. The formation of ternary complex lowers 
the activation energy needed for the full escape of bifunctional ligand and 
subsequent binding of the competitive ligand. 
 
 
Figure 10. Reaction path for a possible mechanism of dissociation rate facilitation by 
the competitive inhibitor from protein kinase (blue structure). The lower energy for the 
complex with monofunctional inhibitor (orange triangle) indicates the conditions of the 
system where the concentration of the latter greatly exceeds a concentration of the 
bifunctional ligand (green structure). 
 
The proposed description of the facilitated dissociation is in accord with the 
acknowledged model of avidity or “forced proximity” of bifunctional ligands, 
mostly discussed in case of antibodies (Vauquelin and Van Liefde 2012). A 
brief description of facilitated dissociation phenomenon has been given for 
complex between a homobifunctional inhibitor and a dimer of synthetic carbonic 
anhydrase II [(CAII)2] (Mack et al. 2012). Herein, competitive inhibitor 
facilitated the dissociation of a bimolecular complex, in which the hetero-
bifunctional ligand binds into two distinct binding sites separated by a short 
distance of 1.5 nm within a single protein. 
  
G
ib
bs
 fr
ee
 e
ne
rg
y 
of
 th
e 
sy
st
em
 
Reaction coordinate 
46 
6. CONCLUSIONS 
The current thesis is focused on the characterization and application of 
bifunctional ligands, adenosine analogue and oligo-arginine conjugates (ARCs), 
for studying protein kinases in biochemical assays and intracellular format. The 
literature overview briefly introduces the basics of proteins, the importance of 
protein-protein interactions (PPIs) in living cells, inhibitors of protein kinases 
and PPIs, and methods involved in protein studies. These topics are relevant in 
regard to the main results of this thesis, which are summarized as follows: 
 ARC-Lum probes were discovered which exhibit protein binding-induced 
long-lifetime photoluminescence property. The rationale for employing such 
probes in biochemical assays and cellular applications was discussed. 
 The assay based on time-resolved measurement of luminescence (TRL) 
intensity using ARC-Lum probes was validated for the screening of protein 
kinase inhibitors possessing affinities in a wide range. 
 Structure-affinity studies supported by the TRL assay, thermal shift assay, 
and isothermal titration calorimetry combined with the information obtained 
from X-ray analysis of co-crystal structures led to the development of novel 
ARC-type bifunctional ligands possessing one-digit picomolar affinity 
towards PKAc. Novel series of ARCs was characterized in TRL assay 
towards protein kinases PKAc, PKBγ, and ROCKII. 
 Based on successful disruption by ARCs of a stable protein complex (PKA 
holoenzyme) possessing KD value of 100 pM formed between PKA subunits 
PKAr and PKAc. An approach was proposed for targeting strong PPIs with 
bifunctional inhibitors possessing a PPI-competitive moiety along with 
“affinity hook” that occupies an adjacent and well-defined binding site. 
 TRL assay for the measurement of dissociation kinetics of a complex between 
a protein kinase and inhibitor was developed and characterized. 
 Facilitated dissociation kinetics of a complex between a bifunctional ligand 
and protein kinase was discovered. This property was further characterized 
and possible explanations for the phenomenon were discussed. 
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7. SUMMARY IN ESTONIAN 
Bifunktsionaalsed inhibiitorid ja fotoluminestsents-sondid 
valgukomplekside uurimiseks 
Raku elutegevust reguleerivad signaalirajad moodustavad keerulise süsteemi, 
milles omavad keskset rolli proteiinkinaasid. Proteiinkinaasid katalüüsivad 
fosforüülrühma ülekannet nukleotiidilt sihtvalgule, mõjutades seeläbi sihtvalgu 
funktsioone nagu lokalisatsioon ja aktiivsus. Kõrvalekalded normaalsest pro-
teiinkinaasi aktiivsusest, mis on valdavalt põhjustatud geenimutatsioonidest või 
häiretest ekspressioonis, võivad põhjustada raskesti ravitavaid haigusi nagu 
neurodegeneratiivsed (Parkinson, Alzheimer) ja südame-veresoonkonna hai-
gused, diabeet ning vähkkasvajad (Tönges et al. 2012; Cho et al. 2001; Morgan-
Fisher et al. 2013). Proteiinkinaaside aktiivsuse reguleerimine väikese molekul-
massiga inhibiitoritega on seetõttu ravimiarenduse pingsa tähelepanu all ning 28 
proteiinkinaaside inhibiitorit on kasutusel vähiravimina (Wu et al. 2016). 
Ravimikandidaatide arendustöö toetamiseks on vajalikud efektiivsed bio-
keemilised meetodid, mis võimaldavad potentsiaalsete inhibiitorite kiiret 
tuvastamist ja nende toimemehhanismide iseloomustamist.  
Käesoleva töö tulemusena töötati välja ja iseloomustati uudne meetod 
biokeemilisteks katseteks, mis põhineb orgaanilise madalmolekulaarse sondi 
(ARC-Lum-sondi) aeglase kustumisega luminestsentsi eluea mõõtmisel. Tartu 
Ülikooli keemia instituudis välja arendatud ARC-Lum-sondid on bifunktsio-
naalsed proteiinkinaaside inhibiitorid, mis koosnevad ATP sidumistaskusse 
seonduvast tiofeeni või selenofeeni fragmenti sisaldavast osast, valk-sub-
straadiga konkureerivast peptiidsest fragmendist ja neid ühendavast linkerist. 
Ergastamisel lähis-UV kiirgusega avastati sisemolekulaarne Förster-tüüpi reso-
nantse energia ülekande (FRET) mehhanism tiofeeni või selenofeeni frag-
mendilt (FRET-doonor) peptiidse fragmendi külge konjugeeritud fluorivärvile 
(FRET-aktseptor) [ARC-Lum(Fluo)]. Seostumata ARC-Lum(Fluo) luminestsents 
sumbus kiiresti (< 10 ns), proteiinkinaasiga kompleksis pikenes luminestsentsi 
eluiga 20–270 mikrosekundini, sõltuvalt proteiinkinaasist. Valgu sidumisest 
sõltuv luminestsentsi pikk eluiga võimaldab ARC-Lum(Fluo)-sonde kasutada 
aegviivitusega mõõterežiimis, vähendades märgatavalt mittespetsiifiliste sig-
naalide mõjusid. Vastav omadus võimaldas iseloomustada mitme basofiilse 
proteiinkinaasi aktiivsust biokeemilises analüüsimeetodis, inhibiitorite sidumise 
efektiivsust laias afiinsuste vahemikus, proteiinkinaas:inhibiitor-kompleksi dis-
sotsiatsioonikineetikat ja jälgida reaalajas proteiinkinaasi aktiivsust imetaja-
rakkudes. 
Mahukate struktuur-aktiivsus uuringute ja ARC:PKAc kooskristallide 
röntgenstruktuur-analüüsi tulemustest lähtudes arendati uudse struktuuriga 
bifunktsionaalsed ARC-tüüpi inhibiitorid, mis saavutasid senikirjeldatud inhi-
biitoritest kõrgema afiinsuse proteiinkinaasi PKAc suhtes (Kd < 10 pM). Nende 
inhibiitorite puhul näidati linkeri pikkuse mõju olulisust afiinsusele ning 
juurutati sünteesiskeem kahe funktsionaalse osa vahelise kauguse varieerimiseks. 
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Pikomolaarse afiinsusega fluorestsents-sondi ARC-1413 kasutati PKA holo-
ensüümi alaühikute (PKAc ja PKAr) vahelise valk-valk interaktsiooni afiinsuse 
määramiseks fluorestsentsanisotroopia meetodil. Saadud tulemus näitas, et 
bifunktsionaalseid inhibiitoreid on võimalik kasutada terapeutiliselt oluliste, 
kuid monofunktsionaalsete inhibiitorite jaoks liigselt kõrge afiinsusega valkude-
vaheliste interaktsioonide lõhkumiseks. Inhibiitorite toimemehhanismi eda-
siseks uurimiseks valmistati lüsaat rakkudest, mis sisaldas geneetiliselt 
muundatud PKA alaühikuid: kollase fluorivalguga PKAc liitvalku (PKAcα-
YFP) ja rohelise fluorivalguga PKAr liitvalku (PKArIIβ-GFP). Bifunktsio-
naalne inhibiitor ARC-1411 lõhkus kontsentratsioonist sõltuvalt PKAcα-
YFP2:PKArIIβ-GFP2 tetrameerse holoensüümi, mis tuvastati luminestsentsi 
intensiivsuste suhte muutumise järgi YFP ja GFP kanalites. PKA alaühikute 
vahelise PPI lõhkumine pikomolaarse afiinsusega (KD = 3 pM) bifunktsionaalse 
inhibiitoriga ARC-1411 toimus üle 20 korra madalamal kontsentratsioonil, kui 
füsioloogilise PKA holoensüümi aktivaatori, sekundaarse virgatsaine cAMP-ga. 
Erinevalt monofunktsionaalsest inhibiitorist H89, mis seondus samuti PKA 
holoensüümiga, omab raku plasmamembraani läbiv ARC-inhibiitor võimet eris-
tada vaba ja seostunud PKAc alaühikut ning soodustab PKAc transporti raku-
membraanidest eemale. 
ARC-sondide abil proteiinkinaaside aktiivsuse jälgimisel rakkudes ja ARC-
inhibiitorite dissotsiatsioonikineetika uurimiste käigus avastati bifunktsionaal-
sete inhibiitorite hõlbustatud dissotsiatsiooni nähtus. Konkureerivad inhibiitorid 
kiirendavad bifunktsionaalse inhibiitori ja proteiinkinaasi vahelise kompleksi 
dissotsiatsiooni. Bifunktsionaalse inhibiitori üks aktiivosa dissotsieerub võrdle-
misi kiiresti, kuid kompleksi täielik dissotsiatsioon on takistatud sünergistiliselt 
teise fragmendi kaudu, mis jääb valguga seotuks. Dissotsieerunud funktsio-
naalse osa assotsiatsioon sidumistaskuga on soodustatud ruumilise läheduse 
tõttu ja sellest tuleneb kompleksi aeglane lagunemine. Konkurentse inhibiitori 
lisamine suures ülehulgas suurendab tõenäosust, et bifunktsionaalse inhibiitori 
osalise dissotsiatsiooni ajal hõivab konkurentne inhibiitor vabanenud sidumis-
tasku, soodustades bifunktsionaalse inhibiitori täielikku dissotsiatsiooni. Avas-
tatud nähtus näitab kompleksi kineetiliste parameetrite iseloomustamise olu-
lisust, kuna hõlbustatud dissotsiatsioon ilmneb mõnede ligandide (näit. ATP) 
füsioloogiliselt saavutatavate kontsentratsioonide juures. 
Uurimistöös kasutati ARC-tüüpi bifunktsionaalseid inhibiitoreid ja fotolumi-
nestsents-sonde mitmekülgseks proteiinkinaaside ja nende inhibiitorite ise-
loomustamiseks. Kirjeldatud bifunktsionaalsete ühendite edukus tugevate valk-
valk interaktsioonide lõhkumisel lisab uudse võimaluse valkude kompleks-
seerumise mõjutamiseks ravieesmärgil. 
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